Atarim Launches Market-First Fully Embedded AI Creative Team Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor…
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b…
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference
ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b…
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment…
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis”…
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Media Release SYDNEY,…
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achieved Media Release SYDNEY,…
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation…
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation…
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood…
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood…
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology…
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology…